Literature DB >> 12391041

Hypoxic and hypercapnic drives to breathe generate equivalent levels of air hunger in humans.

S H Moosavi1, E Golestanian, A P Binks, R W Lansing, R Brown, R B Banzett.   

Abstract

Anecdotal observations suggest that hypoxia does not elicit dyspnea. An opposing view is that any stimulus to medullary respiratory centers generates dyspnea via "corollary discharge" to higher centers; absence of dyspnea during low inspired Po(2) may result from increased ventilation and hypocapnia. We hypothesized that, with fixed ventilation, hypoxia and hypercapnia generate equal dyspnea when matched by ventilatory drive. Steady-state levels of hypoxic normocapnia (end-tidal Po(2) = 60-40 Torr) and hypercapnic hyperoxia (end-tidal Pco(2) = 40-50 Torr) were induced in naive subjects when they were free breathing and during fixed mechanical ventilation. In a separate experiment, normocapnic hypoxia and normoxic hypercapnia, "matched" by ventilation in free-breathing trials, were presented to experienced subjects breathing with constrained rate and tidal volume. "Air hunger" was rated every 30 s on a visual analog scale. Air hunger-Pet(O(2)) curves rose sharply at Pet(O(2)) <50 Torr. Air hunger was not different between matched stimuli (P > 0.05). Hypercapnia had unpleasant nonrespiratory effects but was otherwise perceptually indistinguishable from hypoxia. We conclude that hypoxia and hypercapnia have equal potency for air hunger when matched by ventilatory drive. Air hunger may, therefore, arise via brain stem respiratory drive.

Entities:  

Mesh:

Year:  2002        PMID: 12391041     DOI: 10.1152/japplphysiol.00594.2002

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  32 in total

1.  The air hunger response of four elite breath-hold divers.

Authors:  Andrew P Binks; Andrea Vovk; Massimo Ferrigno; Robert B Banzett
Journal:  Respir Physiol Neurobiol       Date:  2007-07-01       Impact factor: 1.931

Review 2.  Retrotrapezoid nucleus, respiratory chemosensitivity and breathing automaticity.

Authors:  Patrice G Guyenet; Douglas A Bayliss; Ruth L Stornetta; Michal G Fortuna; Stephen B G Abbott; Seth D DePuy
Journal:  Respir Physiol Neurobiol       Date:  2009-02-13       Impact factor: 1.931

3.  Reliability and validity of the multidimensional dyspnea profile.

Authors:  Paula M Meek; Robert Banzett; Mark B Parsall; Richard H Gracely; Richard M Schwartzstein; Robert Lansing
Journal:  Chest       Date:  2012-01-19       Impact factor: 9.410

4.  The Effect of Aerosol Saline on Laboratory-Induced Dyspnea.

Authors:  C R O'Donnell; R W Lansing; R M Schwartzstein; Robert Banzett
Journal:  Lung       Date:  2016-12-21       Impact factor: 2.584

Review 5.  Central respiratory chemoreception.

Authors:  Patrice G Guyenet; Ruth L Stornetta; Douglas A Bayliss
Journal:  J Comp Neurol       Date:  2010-10-01       Impact factor: 3.215

6.  Aerosol furosemide for dyspnea: Controlled delivery does not improve effectiveness.

Authors:  Capucine Morélot-Panzini; Carl R O'Donnell; Robert W Lansing; Richard M Schwartzstein; Robert B Banzett
Journal:  Respir Physiol Neurobiol       Date:  2017-10-12       Impact factor: 1.931

Review 7.  The multiple dimensions of dyspnea: review and hypotheses.

Authors:  Robert W Lansing; Richard H Gracely; Robert B Banzett
Journal:  Respir Physiol Neurobiol       Date:  2008-07-25       Impact factor: 1.931

Review 8.  Chemoreception and asphyxia-induced arousal.

Authors:  Patrice G Guyenet; Stephen B G Abbott
Journal:  Respir Physiol Neurobiol       Date:  2013-04-19       Impact factor: 1.931

Review 9.  Physiologic changes and clinical correlates of advanced dyspnea.

Authors:  Sean A Gilman; Robert B Banzett
Journal:  Curr Opin Support Palliat Care       Date:  2009-06       Impact factor: 2.302

10.  The affective dimension of laboratory dyspnea: air hunger is more unpleasant than work/effort.

Authors:  Robert B Banzett; Sarah H Pedersen; Richard M Schwartzstein; Robert W Lansing
Journal:  Am J Respir Crit Care Med       Date:  2008-03-27       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.